Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma-Reference-Cited by-同舟云学术

Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma

Published:2019-03 Issue:3 Volume:25 Page:459-465
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Bhutani Manisha,Foureau David,Zhang Qing,Robinson Myra,Wynn Adina S.,Steuerwald Nury M.,Druhan Lawrence J.^ORCID,Guo Fei,Rigby Katherine,Turner Mitchell,Slaughter Daniel,Friend Reed,Atrash Shebli,Symanowski James T.,Avalos Belinda R.,Copelan Edward A.,Voorhees Peter M.,Usmani Saad Z.

Funder

Conquer Cancer Foundation

Heineman Foundation

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference25 articles.

1. Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma;Fauriat;Leukemia,2006

2. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody;Benson;Blood,2010

3. The expression of T cell related costimulatory molecules in multiple myeloma;Brown;Leuk Lymph,1998

4. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma;Muthu Raja;PLoS One,2012

5. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow;Ramachandran;J Immunol,2013

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural killer cells affect the natural course, drug resistance, and prognosis of multiple myeloma;Frontiers in Cell and Developmental Biology;2024-02-12

2. A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse;Clinical Lymphoma Myeloma and Leukemia;2023-07

3. Cellular immunity in the era of modern multiple myeloma therapy;International Journal of Cancer;2023-06-12

4. Treatment Strategy for Ultra-High-Risk Multiple Myelomas with Chromosomal Aberrations Considering Minimal Residual Disease Status and Bone Marrow Microenvironment;Cancers;2023-04-22

5. Natural Killer Cells Are Key Host Immune Effector Cells Affecting Survival in Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation;Cells;2022-11-02